138 related articles for article (PubMed ID: 38458185)
1. SWI/SNF regulation of germinal center fate and lymphomagenesis.
Sievers Q; Abdel-Wahab O
Cancer Cell; 2024 Apr; 42(4):507-509. PubMed ID: 38458185
[TBL] [Abstract][Full Text] [Related]
2. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
[TBL] [Abstract][Full Text] [Related]
3. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
4. SWI/SNF catalytic subunits' switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells.
Wu S; Fatkhutdinov N; Fukumoto T; Bitler BG; Park PH; Kossenkov AV; Trizzino M; Tang HY; Zhang L; Gardini A; Speicher DW; Zhang R
Nat Commun; 2018 Oct; 9(1):4116. PubMed ID: 30297712
[TBL] [Abstract][Full Text] [Related]
5. SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions.
Deng Q; Lakra P; Gou P; Yang H; Meydan C; Teater M; Chin C; Zhang W; Dinh T; Hussein U; Li X; Rojas E; Liu W; Reville PK; Kizhakeyil A; Barisic D; Parsons S; Wilson A; Henderson J; Scull B; Gurumurthy C; Vega F; Chadburn A; Cuglievan B; El-Mallawany NK; Allen C; Mason C; Melnick A; Green MR
Cancer Cell; 2024 Apr; 42(4):605-622.e11. PubMed ID: 38458188
[TBL] [Abstract][Full Text] [Related]
6. The clinicopathological significance of SWI/SNF alterations in gastric cancer is associated with the molecular subtypes.
Huang SC; Ng KF; Chang IY; Chang CJ; Chao YC; Chang SC; Chen MC; Yeh TS; Chen TC
PLoS One; 2021; 16(1):e0245356. PubMed ID: 33481850
[TBL] [Abstract][Full Text] [Related]
7. SWI/SNF protein expression status in fumarate hydratase-deficient renal cell carcinoma: immunohistochemical analysis of 32 tumors from 28 patients.
Agaimy A; Amin MB; Gill AJ; Popp B; Reis A; Berney DM; Magi-Galluzzi C; Sibony M; Smith SC; Suster S; Trpkov K; Hes O; Hartmann A
Hum Pathol; 2018 Jul; 77():139-146. PubMed ID: 29689242
[TBL] [Abstract][Full Text] [Related]
8. Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors.
Abou Alaiwi S; Nassar AH; Xie W; Bakouny Z; Berchuck JE; Braun DA; Baca SC; Nuzzo PV; Flippot R; Mouhieddine TH; Spurr LF; Li YY; Li T; Flaifel A; Steinharter JA; Margolis CA; Vokes NI; Du H; Shukla SA; Cherniack AD; Sonpavde G; Haddad RI; Awad MM; Giannakis M; Hodi FS; Liu XS; Signoretti S; Kadoch C; Freedman ML; Kwiatkowski DJ; Van Allen EM; Choueiri TK
Cancer Immunol Res; 2020 Aug; 8(8):1075-1084. PubMed ID: 32321774
[TBL] [Abstract][Full Text] [Related]
9. Relationship between cellular morphology and abnormality of SWI/SNF complex subunits in pancreatic undifferentiated carcinoma.
Yamamoto T; Kohashi K; Yamada Y; Kawata J; Sakihama K; Matsuda R; Koga Y; Aishima S; Nakamura M; Oda Y
J Cancer Res Clin Oncol; 2022 Nov; 148(11):2945-2957. PubMed ID: 34817661
[TBL] [Abstract][Full Text] [Related]
10. ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis.
Barisic D; Chin CR; Meydan C; Teater M; Tsialta I; Mlynarczyk C; Chadburn A; Wang X; Sarkozy M; Xia M; Carson SE; Raggiri S; Debek S; Pelzer B; Durmaz C; Deng Q; Lakra P; Rivas M; Steidl C; Scott DW; Weng AP; Mason CE; Green MR; Melnick A
Cancer Cell; 2024 Apr; 42(4):583-604.e11. PubMed ID: 38458187
[TBL] [Abstract][Full Text] [Related]
11. SWI/SNF Alterations in Squamous Bladder Cancers.
Achenbach F; Rose M; Ortiz-Brüchle N; Seillier L; Knüchel R; Weyerer V; Hartmann A; Morsch R; Maurer A; Ecke TH; Garczyk S; Gaisa NT
Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33227989
[TBL] [Abstract][Full Text] [Related]
12. Switch/sucrose-non-fermentable (SWI/SNF) complex (SMARCA4, SMARCA2, INI1/SMARCB1)-deficient colorectal carcinomas are strongly associated with microsatellite instability: an incidence study in 4508 colorectal carcinomas.
Ahadi MS; Fuchs TL; Clarkson A; Sheen A; Sioson L; Chou A; Gill AJ
Histopathology; 2022 May; 80(6):906-921. PubMed ID: 34951482
[TBL] [Abstract][Full Text] [Related]
13. SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition.
Alessi JV; Ricciuti B; Spurr LF; Gupta H; Li YY; Glass C; Nishino M; Cherniack AD; Lindsay J; Sharma B; Felt KD; Rodig SJ; Cheng ML; Sholl LM; Awad MM
J Thorac Oncol; 2021 Jul; 16(7):1176-1187. PubMed ID: 33845210
[TBL] [Abstract][Full Text] [Related]
14. The SWI/SNF chromatin-remodeling complex and glucocorticoid resistance in acute lymphoblastic leukemia.
Pottier N; Yang W; Assem M; Panetta JC; Pei D; Paugh SW; Cheng C; Den Boer ML; Relling MV; Pieters R; Evans WE; Cheok MH
J Natl Cancer Inst; 2008 Dec; 100(24):1792-803. PubMed ID: 19066270
[TBL] [Abstract][Full Text] [Related]
15. Residual complexes containing SMARCA2 (BRM) underlie the oncogenic drive of SMARCA4 (BRG1) mutation.
Wilson BG; Helming KC; Wang X; Kim Y; Vazquez F; Jagani Z; Hahn WC; Roberts CW
Mol Cell Biol; 2014 Mar; 34(6):1136-44. PubMed ID: 24421395
[TBL] [Abstract][Full Text] [Related]
16. The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer.
Soldi R; Ghosh Halder T; Weston A; Thode T; Drenner K; Lewis R; Kaadige MR; Srivastava S; Daniel Ampanattu S; Rodriguez Del Villar R; Lang J; Vankayalapati H; Weissman B; Trent JM; Hendricks WPD; Sharma S
PLoS One; 2020; 15(7):e0235705. PubMed ID: 32649682
[TBL] [Abstract][Full Text] [Related]
17. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
18. Coffin-Siris syndrome is a SWI/SNF complex disorder.
Tsurusaki Y; Okamoto N; Ohashi H; Mizuno S; Matsumoto N; Makita Y; Fukuda M; Isidor B; Perrier J; Aggarwal S; Dalal AB; Al-Kindy A; Liebelt J; Mowat D; Nakashima M; Saitsu H; Miyake N; Matsumoto N
Clin Genet; 2014 Jun; 85(6):548-54. PubMed ID: 23815551
[TBL] [Abstract][Full Text] [Related]
19. SWI/SNF-deficiency defines highly aggressive undifferentiated endometrial carcinoma.
Tessier-Cloutier B; Coatham M; Carey M; Nelson GS; Hamilton S; Lum A; Soslow RA; Stewart CJ; Postovit LM; Köbel M; Lee CH
J Pathol Clin Res; 2021 Mar; 7(2):144-153. PubMed ID: 33125840
[TBL] [Abstract][Full Text] [Related]
20.
Concepcion CP; Ma S; LaFave LM; Bhutkar A; Liu M; DeAngelo LP; Kim JY; Del Priore I; Schoenfeld AJ; Miller M; Kartha VK; Westcott PMK; Sánchez-Rivera FJ; Meli K; Gupta M; Bronson RT; Riely GJ; Rekhtman N; Rudin CM; Kim CF; Regev A; Buenrostro JD; Jacks T
Cancer Discov; 2022 Feb; 12(2):562-585. PubMed ID: 34561242
[No Abstract] [Full Text] [Related]
[Next] [New Search]